IRAK3

Across TCGA pan-cancer cohorts, IRAK3 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated IRAK3 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IRAK3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IRAK3 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

HNSC, SARC, and SKCM are the cancer types where IRAK3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.134	0.628	<.001	19	view →
SARC	OS	Median	All	0.183	0.839	<.001	12	view →
SKCM	DFS	Median	II,III,IV	0.938	0.539	.010	11	view →
UCEC	DFS	Median	All	0.970	0.827	.016	10	view →
PRAD	DFS	Median	All	0.434	0.888	<.001	6	view →
BLCA	DFS	Median	IV	0.139	0.479	.034	6	view →
LUSC	OS	Median	All	0.011	0.819	<.001	6	view →
LIHC	OS	Median	All	0.255	0.773	.012	6	view →
GBM	DFS	Median	All	1.000	0.204	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

IRAK3–HNSC (DFS)

Open the HNSC breakdown →